Avidity begins Cohort C enrollment in FORTITUDE trial Avidity Biosciences has begun enrollment of Cohort C of the Phase 1/2 FORTITUDE™ clinical trial. Below is Avidity’s letter to the FSHD… Read More »
Avidity begins Cohort C enrollment in FORTITUDE trial
Fall vaccine guide
Via Ranae Beeker, RN, here’s a clear and concise guide to recommended vaccines, updated for the fall of 2024. For people with neuromuscular conditions, this is especially important because: Falling… Read More »
Mighty micro RNAs
by Yi-Wen Chen, PhD, Children’s National Hospital, Washington DC Many Nobel Prize-winning discoveries have contributed to the advancement of research and treatments for facioscapulohumeral muscular dystrophy (FSHD), and the work… Read More »
Are you prepared for an emergency?
The catastrophic impact of Hurricane Helene is a sobering reminder of the importance of being prepared for disasters and the special care people with disabilities need to take. One handy… Read More »
Aging in place – Tips for planning ahead
Notes by Helen Cave on behalf of the Wellness Hour Life brings change. Life would be boring if it didn’t encompass change. Yet the changes that FSHD brings to us… Read More »